HomeInvesting NewsLong-Term Statistics on Lynparza by AstraZeneca/Merck Demonstrate a Benefit for Survival in...

Long-Term Statistics on Lynparza by AstraZeneca/Merck Demonstrate a Benefit for Survival in Ovarian Cancer Patients

Published on

Lynparza by AstraZeneca/Merck

Long-term data from two phase 3 trials show the new drug developed by AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) Lynparza and clinically used in first-line therapies showed significant survival in some ovarian cancer patients.

AstraZeneca presented long-term results from a phase 3 study of olaparib as a monotherapy as well as 5-year follow-up data from a study called PAOLA-1 of Lynparza (olaparib) as a combination therapy (ESMO).

PAOLA-1:

In recently released PAOLA-1 data, Lynparza plus Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) Avastin (bevacizumab) increased median Overall Survival (OS) to 56.5 months, compared to 51.6 months with bevacizumab alone, in patients with newly diagnosed advanced ovarian cancer regardless of HRD status, according to AstraZeneca in a press release on September 9. 

According to the manufacturer, olaparib + Avastin reduced the probability of death in HRD-positive patients by 38% when compared to Avastin, leading to a clinically significant improvement in overall survival.

In comparison to individuals treated with Avastin alone, 65.5% of those treated with Lynparza and Avastin were still alive at five years, according to AstraZeneca.

The Lynparza/Avastin combination also increased median Progression-Free Survival (PFS; the amount of time a patient experiences the disease during or after therapy without it getting worse) to nearly four years (46.8 months), as opposed to 17.6 months with Avastin plus placebo.

Additionally, compared to 19.2% of patients receiving Avastin alone, 46.1% of patients receiving Lynparza/Avastin are still progression-free at five years.

SOLO-1:

Updated SOLO-1 study results show Lynparza reduced the risk of death by 45% in patients with newly-diagnosed advanced ovarian cancer with the BRCA mutation (BRCAm). This was in comparison to placebo.

Compared to 75.2 months for the placebo, olaparib’s median OS has not yet been attained, according to AstraZeneca.

67% of patients were still alive at the time of the seven-year OS study, compared to 47% of placebo patients.

Additionally, according to the business, the drug’s median time to first subsequent therapy was 64 months as opposed to 15.1 months for placebo. According to AstraZeneca, the safety profile in both trials matched that of earlier research.

Premarket Sept. 9: AZN +1.82% to $61.42

Featured Image-  Megapixl @Michaelvi

Please See Disclaimer

Latest News

DWAC Stock Price Up as SPAC Switches to a PO Box at a UPS Location as Its New Address

DWAC stock price was trading at 17.52 as of 03:52 PM EDT - a...

Meta Stock Slides as Firm Tests New Account Switching, Facebook, and Instagram Navigation

Meta stock today traded at 137.37 as of 03:40 PM EDT on Sept 26 For...

The Cause of Monday’s Amazon Stock Rally

Amazon Stock (NASDAQ:AMZN) Amazon stock was up as much as 3.1% on Monday morning. The...

The Reason Why AMC Stock Is Falling Today

AMC Stock (NYSE:AMC) On Monday morning, news of the company's newly minted AMC Preferred Equity...

More like this

General Motors Stock Plummeted After Partnering With Lithion & Toledo to Boost EVS.

General Motors Stock (NYSE:GM) General Motors stock plunged after it announced that its investment arm,...

Verizon Stock Price Falls After Company Announces Aid for Puerto Rico Disaster Relief.

Verizon Stock (NYSE:VZ) Verizon stock declined after announcing it has pledged $100,000 to the American...

Alphabet Stock Rises as the Launch of New Pixel Smartphones and the Pixel Watch Are Anticipated Next Week

Alphabet stock was trading at $99.12 at 11:50 AM EDT Next week, Google (NASDAQ:GOOG) (NASDAQ:GOOGL)...

Raytheon Stock Plunged After It Said It Won a $160 Million Contract for a Dual-Band Radar.

Raytheon Stock (NYSE:RTX) Raytheon stock declined after the company announced that it had just won...

Jblu Stock up and Joins American Airlines to Defend Their Alliance in Court

JBLU stock was up, trading at 6.99 as of 10:21 AM EDT on Monday The...

Target Stock Falls as the Retailer Promised to Provide Excellent Holiday Savings and Values.

Target Stock (NYSE:TGT) To match the excitement of holiday customers, stores have started preparing for...